AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data.
Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good
AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im
NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.
Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done.
